TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007
July 23 2018 - 4:01PM
REGULATED INFORMATIONPRESS
RELEASE
Transparency notification pursuant to Article
14 of the Law of May 2, 2007
Leuven (Belgium) - July 23, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix")
announced today that it received a transparency notification
pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding
the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions.
Summary of the notification
On July 18, 2018, TiGenix received a
transparency notification from Takeda Pharmaceutical Company
Limited following the acquisition of voting securities or voting
rights on July 10, 2018, after which Takeda Pharmaceutical Company
Limited (including through its subsidiary Takeda Pharmaceuticals
International AG) holds 295,908,082 voting rights in TiGenix
(96.08% of the total number of voting rights). As a result Takeda
Pharmaceutical Company Limited crossed the 95% threshold of the
total voting rights of TiGenix.
Content of the notification
Date of the notification: July 17, 2018.
Reason of the notification: acquisition or
disposal of voting securities or voting rights.
Persons subject to the notification requirement:
Takeda Pharmaceutical Company Limited (with address at 1-1
Doshomachi 4-Chome, Chuo-ku, Osaka 540-8645, Japan), who is a
parent undertaking/controlling person.
Date on which the threshold was crossed: July
10, 2018.
Threshold that was crossed: 95%.
Denominator: 307,973,027.
Details of the notification: following the
acquisition of voting securities or voting rights, the number of
voting rights was as follows:
- Takeda Pharmaceutical Company Limited held 284,256,304 voting
securities (92.30% of the total number of voting rights); and
- Takeda Pharmaceuticals International AG held 11,651,778 voting
securities (3.78% of the total number of voting rights);
Total: 295,908,082 voting rights (96.08% of the total number of
voting rights).
Chain of controlled undertakings through which
the holdings are effectively held: Takeda Pharmaceuticals
International AG is controlled by Takeda Pharma A/S, which is
controlled by Takeda A/S, which is controlled by Takeda
Pharmaceutical Company Limited and by Takeda Europe Holdings B.V.,
which is controlled by Takeda Pharmaceutical Company Limited.
Takeda Pharmaceutical Company Limited is not a controlled
entity.
This press release and the above-mentioned transparency
notification can be consulted on our website:
- press release:
http://tigenix.com/news-media/press-releases
- notifications:
http://tigenix.com/investors/share-information/shareholder-overview
For more information:
TiGenixClaudia JiménezSenior Director Investor
Relations and CommunicationsTel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024